ADMA BIOLOGICS, INC. 8-K

What Happened
On May 4, 2026, ADMA Biologics, Inc. (ADMA) announced via press release that the U.S. Food and Drug Administration approved a supplemental Biologics License Application to expand the label for ASCENIV™. The approval adds pediatric immunocompromised patients aged two years and older to the product’s indicated population. The press release was attached to the company’s Form 8‑K (Exhibit 99.1).

Key Details

• Date of announcement: May 4, 2026.
• Regulatory action: FDA approved a label expansion (supplemental BLA) for ASCENIV™.
• New indication: Pediatric immunocompromised patients aged ≥2 years.
• Filing: Announcement made in an 8‑K with the press release included as Exhibit 99.1.

Why It Matters
This is a regulatory milestone that formally expands the approved patient population for ASCENIV, potentially increasing the drug’s addressable market by including younger pediatric patients with immune compromise. For investors, the approval signals commercial and clinical progress for ADMA’s lead product and may influence future revenue prospects and market perception. The 8‑K does not include financial results or projections.